Reduction of Depression Symptoms via the Metabolites of Gut Microbiota


Mawaldı I., Yılmaz A.

12th International Symposium on Health Informatics and Bioinformatics (HIBIT) 2019, İzmir, Türkiye, 17 - 18 Ekim 2019, ss.218

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: İzmir
  • Basıldığı Ülke: Türkiye
  • Sayfa Sayıları: ss.218

Özet

Depression is a common mental disorder and according to World
Health Organization, globally more than 300 million people of
all ages suffer from depression[1]. Even though, until now the real
reason behind depression is unknown, but in most depressive patients
low levels of serotonin are detected and because serotonin is a mood
controlling neurotransmitter, depression also called mood disorder.
Most of the treatments aimed to elevate the serotonin levels but at the
same time, these treatments have many side effects[2].
In this study, we aimed to reveal possible metabolites produced by gut
microbiota that can elevate serotonin levels by inhibiting tryptophan
degradation which is called kynurenine pathway that is a competitive
pathway with serotonin synthesis from tryptophan.
So, we combine many datasets that contain information about the
reactions including their products that gut bacteria can catalyze them
by expressing the catalyzing enzymes. These datasets are taken from
many databases including Brenda, ChEBI, MetanetX, Uniprot, and
Microbiome databases. We used R for data analysis steps.
We ended with three distinct reactions catalyzed by two distinct
enzymes expressed by eight distinct species of gut bacteria.


References:

[1] ‘WHO | Depression’. [Online]. Available:
https://www.who.int/mental_health/management/depression/en/.
[2] M. Vaváková, Z. Ďuračková, and J. Trebatická, ‘Markers of
Oxidative Stress and
Neuroprogression in Depression Disorder’, Oxid. Med. Cell. Longev.,
vol. 2015, pp. 1–12, 2015.